Captain T Cell

🙌 What happened this summer? For the first time ever, the FDA approved a TCR-engineered T cell therapy (#Tecerla from Adaptimmune) for a solid tumor—specifically synovial sarcoma. 💪 Our CEO, Felix Lorenz, shared his thoughts on this breakthrough: "The approval of Adaptimmune's TCR-based T cell therapy is a major milestone for patients and the entire cell therapy landscape. It's the first time we've seen a genetically modified T cell therapy for solid tumors reach the market. I'm confident we'll witness even more success in this field. At Captain T Cell, we're pioneering the next generation of TCR-T cell therapies, including off-the-shelf solutions, with the goal of expanding to new patient groups, boosting efficiency, and simplifying production." For more insights and expert opinions from Immatics and Medigene AG, check out the full article: https://lnkd.in/dmHkyBK8 (You may use www.DeepL.com to translate it from German into English) transkript Georg Kääb #Biotech #TCellTherapy #TCR #CancerResearch #SynovialSarcoma

🚀 Announcement of Strategic Partnership with Charles River We are thrilled to announce a strategic partnership of Captain T Cell with Charles River Laboratories to accelerate our mission of developing a new generation of TCR-T cell therapies for solid tumor patients. Charles River, a global leader in manufacturing services (CDMO), supports drug development companies in bringing novel drugs to patients. Captain T Cell has been selected to participate in Charles River’s new Cell and Gene Therapy (CGT) Accelerator Program (CAP). 🌟 Highlights of the Accelerator Program: - Access to plasmid and vector manufacturing capabilities - Expert advisory services 🤝 Quotes: “We are thrilled to work with the Captain T Cell team to support the manufacture of its TCR-T cell cancer immunotherapy.” - Kerstin Dolph, SVP, Global Manufacturing, Charles River Laboratories “Captain T Cell is devoted to developing a new generation of toolbox-engineered T cell-based immunotherapies for solid tumor patients. We have the utmost confidence in the expertise of Charles River as we work to bring our lead candidate to the clinic.” - Felix Lorenz, CEO, Captain T Cell 📣 Read the full press release here: https://lnkd.in/efPbxCr5 #TCellTherapy #TCR #CancerResearch #Immunotherapy #VentureCapital #Biotech #HealthcareInnovation

https://lnkd.in/eTtdrDnh